Drug-resistant and extensively drug-resistant tuberculosis in southern Africa

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 3, 2010, Pages 180-185

  Grobusch, Martin Peter ^a,b,c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b ALBERT SCHWEITZER HOSPITAL   (Gabon)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Extensive drug resistance; HIV AIDS; Multidrug resistance; Southern Africa; Tuberculosis

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; GATIFLOXACIN; MOXIFLOXACIN; PLACEBO; RIFAPENTINE;

ALCOHOLISM; BACTERIAL STRAIN; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DRUG MECHANISM; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; REVIEW; SOUTH AFRICA; SPUTUM ANALYSIS; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; DEVELOPING COUNTRIES; DISEASE OUTBREAKS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; INCIDENCE; MALE; NEEDS ASSESSMENT; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; RISK ASSESSMENT; SOCIOECONOMIC FACTORS; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77951043504     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283378680     Document Type: Review

References (45)

1. Wolinsky E, Reginster A, Steenken W Jr. Drug-resistant tubercle bacilli in patients under treatment with streptomycin. Am Rev Tuberc 1948; 58:335-343.
2. Global tuberculosis control. A short update to the 2009 report. Geneva: WHO; 2009. http://www.who.int/tb/publication/global-report/2009/update/ tbu-9.pdf. [Accessed 29 December 2009]
3. Abdool Karim SS, Churchyard G, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 2009; 374:921-933.
4. LoBue P. Extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2009; 22:167-173.
5. Banerjee R, Schecter GF, Flood J, Porco TC. Extensively drug-resistant tuberculosis: new strains, new challenges. Expert Rev Anti Infect Ther 2008; 6:713-724.
6. Ben Amor Y, Nemser B, Singh A, et al. Underreported threat of multidrugresistant tuberculosis in Africa. Emerg Infect Dis 2008; 14:1345-1352.
7. Lönnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med 2008; 29:481-491.
8. Madariaga MG, Lalloo UG, Swindells S. Extensively drug-resistant tuberculosis. Am J Med 2008; 121:835-844.
9. Dye C. Doomsday postponed? Preventing and reversing epidemics of drugresistant tuberculosis. Nat Rev Microbiol 2009; 7:81-87.
10. Jassal M, Bishai WR. Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009; 9:19-30.
11. Lalloo UG, Pillay S. Managing tuberculosis and HIV in sub-Saharan Africa. Curr HIV/AIDS Rep 2008; 5:132-139.
12. Shenoi S, Heysell S, Moll A, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr Opin Infect Dis 2009; 22:11-17.
13. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009; 4:325-333.
14. Whittaker E, Kampmann B. Perinatal tuberculosis: new challenges in the diagnosis and treatment of tuberculosis in infants and the newborn. Early Hum Dev 2008; 84:795-799.
15. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-1580.
16. Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multidrug resistant tuberculosis? A systematic review. PLoS One 2009; 4:e5561.
17. John MA, Menezes CN, Chita G, et al. High tuberculosis and HIV co-infection rate, Johannesburg. Emerg Infect Dis 2007; 13:795-796.
18. Andrews JR, Gandhi NR, Moodley P, et al. Exogenous re-infection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis 2008; 198:1582-1589.
19. Padayatchi N, Friedland G. Decentralised management of drug-resistant tuberculosis (MDR- and XDR-TB) in South Africa: an alternative model of care. Int J Tuberc Lung Dis 2008; 12:978-980.
20. Zvavamwe Z, Ehlers VE. Experiences of a community-based tuberculosis treatment programme in Namibia: a comparative cohort study. Intern J Nurs Stud 2009; 46:302-309.
21. Basu S, Friedland GH, Medlock J, et al. Averting epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci U S A 2009; 106:7672-7677.
22. Gandhi NR, Moll AP, Lalloo U, et al. Successful integration of tuberculosis and HIV treatment in rural South Africa: the SizonqÕoba study. J Acquir Immune Defic Syndr 2009; 50:37-43.
23. Perumal R, Padayatchi N, Stiefvater E. The whole is greater than the sum of the parts: recognising missed opportunities for an optimal response to the rapidly maturing TB-HIV co-epidemic in South Africa. BMC Publ Health 2009; 9:243.
24. Scano F, Vitoria M, Burman W, et al. Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis 2008; 12:1370-1375.
25. Colebunders R, Worodria W, Jones-Ló pez E, et al. Drug-resistant TB and HIV in resource-limited settings: what TB/HIV programmes can learn from each other. Trop Med Intern Health 2009; 13:1204-1207.
26. Van der Spuy GD, Kremer K, Ndabambi SI, et al. Changing Mycobacterium tuberculosis population highlights clade-specific pathogenic characteristics. Tuberculosis 2009; 89:120-125.
27. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/ KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis 2007; 45:1409-1414.
28. Ioerger TR, Koo S, No EG, et al. Genome analysis of multi and extensively drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One 2009; 4:e7778.
29. Mlambo CK, Warren RM, Poswa X, et al. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis 2008; 12:99-104.
30. Stavrum R, Mphahlele M, Øvreås K, et al. High diversity of Mycobacterium tuberculosis genotypes in South Africa and preponderance of mixed infections among ST53 isolates. J Clin Microbiol 2009; 47:1848-1856.
31. Basu S, Stuckler D, Gonsalves G, Lurie M. The production of consumption: addressing the impact of mineral mining on tuberculosis in southern Africa. Global Health 2009; 5:11.
32. Lönnroth K, Williams BG, Stadlin S, et al. Alcohol use as a risk factor for tuberculosis: a systematic review. BMC Publ Health 2008; 8:289.
33. Rehm J, Samokhvalov AV, Neuman MG, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Publ Health 2009; 9:450.
34. Pepper DJ, Rebe K, Morroni C, et al. Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS One 2009; 4:e4520.
35. Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis 2008; 21:587-595.
36. Shean KP, Willcox PA, Siwendu SN, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/ Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 2008; 12:1182-1189.
37. Seung KJ, Omatayo DB, Keshavjee S, et al. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One 2009; 4:e7186.
38. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9:153-161.
39. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4:e6914.
40. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiological and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33:871-881.
41. Loveday M, Thomson L, Chopra M, Ndlela Z. A health systems assessment of the KwaZulu-Natal tuberculosis programme in the context of increasing drug resistance. Int J Tuberc Lung Dis 2008; 12:1042-1047.
42. Bwanga F, Hoffner S, HaileM, Joloba ML. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis 2009; 9:67.
43. Uys PW, Warren R, van Helden PD, et al. Potential of rapid diagnosis for controlling drug-susceptible and drug-resistant tuberculosis in communities where Mycobacterium tuberculosis infections are highly prevalent. J Clin Microbiol 2009; 47:1484-1490.
44. Ma Z, Lienhardt C. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin Chest Med 2009; 30:755-768.
45. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397-2405.